ReviewPolymers2024
Advancing the Physicochemical Properties and Therapeutic Potential of Plant Extracts Through Amorphous Solid Dispersion Systems.
Review in Polymers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Decoding Cyclodextrins in Skin Applications: Structure, Mechanisms, and Safety in Cosmetic and Dermatologic Formulations (Part I).International journal of molecular sciences · 2026Review
- Amorphous solid dispersions as a strategy to enhance the bioavailability and stability of formulations containing plant active ingredients: An integrative review.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026Review
- The Impact of Polymers in Amorphous Solid Dispersion on the Bioavailability of Sulfonylureas and Meglitinides.Drug design, development and therapy · 2026Review
- Comparative evaluation of ternary amorphous solid dispersions: Identifying optimal excipient systems for enhancing drug solubility.International journal of pharmaceutics: X · 2025Review
- Nanoengineered phytochemicals overcome blood-brain barrier constraints in neurodegenerative disorders.Frontiers in neurologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Plant extracts demonstrate significant potential as a rich source of active pharmaceutical ingredients, exhibiting diverse biological activities and minimal toxicity. However, the low aqueous solubility of extracts and their gastrointestinal permeability, as well as their poor oral bioavailability, limit clinical advancements due to drug delivery problems. An amorphous solid dispersion (ASD) delivers drugs by changing an active pharmaceutical ingredient (API) into an amorphous state to increase the solubility and availability of the API to the body. This research aimed to analyze and summarize the successful advancements of ASD systems derived from plant extracts, emphasizing characterization and the effects on dissolution and pharmacological activity. The results show that ASD systems improve phytoconstituent dissolution, bioavailability, and stability, in addition to reducing dose and toxicity. This research demonstrates the significance of ASD in therapeutic formulations to augment the pharmacological activities and efficacy of medicinal plant extracts. The prospects indicate promising potential for therapeutic applications utilizing ASD systems, alongside medicinal plant extracts for clinical therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.